baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Goldman Sachs Knock-Out ABBV/ DE000GG4SM41 /

19/06/2024 17:56:24	Chg.+0.02	Bid22:00:37	Ask22:00:37	Underlying	Strike price	Expiration date	Option type
1.98EUR	+1.02%	- Bid Size: -	- Ask Size: -	AbbVie Inc	192.4556 USD	31/12/2078	Put

GlobeNewswire 19/06 OSE Immunotherapeutics Reports on its 2024 General Shareholders’ Meeting and the Evolution of the B...

GlobeNewswire 19/06 Jasper Therapeutics Announces Appointment of Svetlana Lucas Ph.D., to its Board of Directors

GlobeNewswire 18/06 CytomX Therapeutics to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Confere...

GlobeNewswire 18/06 CEREVEL STOCK UPDATE: Is $45 Per Share Enough for Cerevel (Nasdaq:CERE)? Contact BFA Law about Ongoi...

GlobeNewswire 17/06 CytomX Therapeutics Promotes Chris Ogden to Chief Financial Officer

GlobeNewswire 17/06 Autonomix Enhances Executive Leadership Team with Appointment of Proven Medical Technology Leader, B...

GlobeNewswire 15/06 CEREVEL STOCK NOTICE: Think $45 Per Share is Too Low for Cerevel (Nasdaq: CERE)? Contact BFA Law abo...

Newsfile Corp 13/06 BioMed X Launches New US Institute in New Haven, CT

GlobeNewswire 13/06 Anima Biotech to Present at the Society for Medicines Research’s Modulating RNA with Oligonucleotide...

GlobeNewswire 13/06 LifeSci Advisors Announces Appointment of Chris Howerton Ph.D.

GlobeNewswire 13/06 CEREVEL SHAREHOLDER REMINDER: Is $45 Per Share Enough for Cerevel (Nasdaq: CERE)? BFA Law is Investi...

GlobeNewswire 13/06 What Employees at the Fortune Best Workplaces in New York, Chicago, Texas, and the Bay Area Value Mo...

GlobeNewswire 12/06 US Gastroenterologists Express Anticipation for Approval of AbbVie’s Skyrizi in Ulcerative Colitis, ...

GlobeNewswire 12/06 OSE Immunotherapeutics KOL Investor Webinar on the Therapeutic Landscape and Unmet Medical Needs in ...

GlobeNewswire 11/06 CEREVEL ALERT: Is $45 Per Share Too Low for Cerevel (Nasdaq: CERE)? BFA Law is Investigating and Urg...

GlobeNewswire 08/06 CEREVEL NEWS NOTIFICATION: BFA Law Alerts Cerevel (Nasdaq: CERE) Shareholders of Investigation into ...

GlobeNewswire 05/06 CEREVEL INVESTIGATION ALERT: Cerevel (Nasdaq: CERE) Investors are Encouraged to Contact BFA Law abou...

GlobeNewswire 05/06 Coherus BioSciences Appoints Rita Karachun, CPA, CGMA to its Board of Directors

GlobeNewswire 05/06 OSE Immunotherapeutics and Nantes University Hospital Present Positive Phase 1/2 Study Evaluating FR...

GlobeNewswire 04/06 Royalty Pharma to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

GlobeNewswire 04/06 BioVie Announces Formation of Advisory Board for Bezisterim in Long COVID

GlobeNewswire 03/06 Royalty Pharma Announces Pricing of $1.5 Billion of Senior Unsecured Notes

GlobeNewswire 03/06 ACQUISITION NEWS: Cerevel’s (Nasdaq: CERE) $45 Merger Offer is Being Investigated for Being Too Low,...

GlobeNewswire 01/06 CERE (NASDAQ) REMINDER: BFA Law Reminds Cerevel Shareholders to Inquire About Ongoing Investigation ...

GlobeNewswire 30/05 OSE Immunotherapeutics Provides Business and Corporate Update

Goldman Sachs Knock-Out ABBV/ DE000GG4SM41 /

If you wish to receive reply to your feedback, please provide your email address.